cervical cancer

Hologic designed its scalable AI-based cytology platform to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.

Yourgene will provide its Elucigene DPYD tests to screen approximately 200 patients each month for the next year.

The supplement adds a collection vial to the BD Onclarity test and includes performance data for the BD Viper LT and the BD COR Systems.

The test detects the presence of two biomarkers within a single cell associated with HPV infections that can progress to cervical cancer.

The expanded test can be used for genotype risk-based patient monitoring to prevent over-treatment, BD has said.

The peer-reviewed study assessed sensitivity rates of HPV testing alone, Pap testing alone, and cotesting with both HPV and Pap tests.

The test, which is used to screen for cervical cancer, was previously approved by the agency for use with the Cobas 4800 system.

The biomarker-based test determines women whose human papillomavirus infections are most likely to be associated with cervical pre-cancers.